Aims Anthracycline‐induced cardiotoxicity (ACT) occurs in 57% of treated patients and
remains an important limitation of anthracycline‐based chemotherapy. In various genetic …

Anthracyclines are an integral part of chemotherapy regimens used to treat a variety of
childhood-onset and adult-onset cancers. However, the development of cardiac dysfunction …

The goal of this study is to give a brief background on the literature supporting the
PharmGKB pathway about doxorubicin action, and provides a summary of this active area of …

Anthracyclines are used in over 50% of childhood cancer treatment protocols, but their
clinical usefulness is limited by anthracycline-induced cardiotoxicity (ACT) manifesting as …

Purpose Anthracycline-induced cardiotoxicity (ACT) is a serious adverse drug reaction
limiting anthracycline use and causing substantial morbidity and mortality. Our aim was to …

Background. The use of anthracyclines as effective antineoplastic drugs is limited by the
occurrence of cardiotoxicity. Multiple genetic variants predictive of anthracycline‐induced …

Anthracyclines play an important role in the management of patients with cancer but the
development of anthracycline-induced cardiotoxicity (ACT) remains a significant concern for …

Aim: To identify novel variants associated with anthracycline-induced cardiotoxicity and to
assess these in a genotype-guided risk prediction model. Patients & methods: Two cohorts …

Anthracyclines are effective chemotherapeutic agents, commonly used in the treatment of a
variety of hematologic malignancies and solid tumors. However, their use is associated with …

Anthracycline‐induced cardiotoxicity (AIC) persists as a significant cause of morbidity and
mortality in cancer survivors. Although many protective strategies have been evaluated …